Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

of docetaxel plus placebo.

In April, sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP® (aflibercept) in combination with the FOLFIRI chemotherapy regimen (folinic acid, 5-fluorouracil, and irinotecan) versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer. The full study results will be presented at an upcoming medical meeting.

In addition to VITAL and VELOUR, the program includes one Phase III trial and one Phase II trial, all of which are fully enrolled. An interim analysis of the VENICE Phase III study evaluating aflibercept as a first-line treatment for hormone-refractory metastatic prostate cancer in combination with docetaxel and prednisone is expected to be conducted by an Independent Data Monitoring Committee in mid 2011. Final results of VENICE are anticipated in 2012. Final results of the AFFIRM Phase II study, evaluating aflibercept as a first-line treatment in metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), are expected during the second half of 2011.

A pediatric hexavalent vaccine (DTP-HepB-Polio-Hib) entered Phase III.

Two compounds entered Phase II

  • SAR110894D, a selective oral H3 receptor antagonist for Alzheimer's disease
  • SAR231893/ REGN668 (partnership with Regeneron), a monoclonal antibody anti IL4-R developed for asthma

  • Two compounds entered Phase I

  • SAR156597, a potential first-in-class bi-specific IL4/IL13 antibody for the treatment of patients with idiopathic pulmonary fibrosis
  • SAR307746/REGN910 (partnership with Regeneron), is a fully human IgG1 monoclonal antibody directed against Ang2 entered Phase I in oncology

  • SSR125543, a CRF1 antagonist, did not meet its endpoint in Phase II trial in patients with de
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

    Related medicine technology :

    1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
    2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
    6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
    7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
    8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
    9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
    10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
    11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 31, 2015  In today,s ever-changing marketplace, call centers ... mobile, increasingly connected, and increasingly impatient with slow service. ... interaction channels and tools is driving call centers to ... According to research by benchmarking firm, Best ... segment in a call center study realize the impact ...
    (Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
    (Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
    Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
    ... DUBLIN, Feb. 15, 2011 Warner Chilcott plc (Nasdaq: ... and full year 2010 financial results prior to the market opening ... issuing a press release, the Company will host a conference call ... AM (Eastern Time) to review the results. To participate in the ...
    ... Boston Scientific Corporation (NYSE: BSX ) ... treat peripheral chronic total occlusions (CTOs).  These acquisitions add ... devices for lower extremity peripheral artery disease.   ... 2010 from S.I. Therapies, Ltd., based in Israel.  The ...
    Cached Medicine Technology:Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 2Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 3Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 4
    (Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers ... the University of Pittsburgh School of Medicine are leading a five-year, $5 million ... sub-Saharan Africa. , A cooperative agreement awarded by the U.S. Agency for ...
    (Date:8/3/2015)... Irving, Texas (PRWEB) , ... August 03, 2015 ... ... awarded an agreement to Seattle-based Genelex to offer pharmacogenetic lab testing and ... care and reduce health care costs. , Annually, more than 8.6 million ...
    (Date:8/3/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today welcomed the announcement by OPKO Health that the US Food and ... treatment for chronic kidney disease (CKD) and vitamin D insufficiency, which uses Catalent’s ...
    (Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... dental services to help patients in need. Most people know that general health emergencies, ... emergency. Unfortunately, a fewer amount of people know where to turn to during a ...
    (Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
    Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Novatus Unveils Milestone Software Release 2
    ... With changes in the nation,s healthcare system looming and overall ... for debut at the Wynn Las Vegas this November has ... into alternative careers. The Medical Fusion conference ( ... that is tapping into the growing frustration of physicians practicing ...
    ... Patient-360(TM) tool optimizes impact of patient education programs. ... For marketers in the pharmaceutical industry, building relationships ... Data Development Worldwide,s Patient-360(TM) market research tool allows ... the patient pathway and then to prioritize and ...
    ... staph bacteria is being transmitted between animals and ... News) -- Transmission of methicillin-resistant staphylococcus aureus (MRSA) ... the most common being infections of the skin, ... a review of clinical evidence. , "Pet owners ...
    ... succeed where others have failed , MONDAY, June 22 (HealthDay ... in the United States could prove to be the toughest ... can reach that long-elusive goal, it would not only guarantee ... history, experts say. , "Assuming that President Obama ...
    ... with Patient and Chamber , , ANAHEIM, Calif., June ... in technology for hyperbaric healthcare, today announced the availability of ... verification of all NFPA (National Fire Protection Association) ... to be fully integrated into any hyperbaric chamber. The new ...
    ... Meeting -- , , News Facts , , ... new report, IDC Health Insights , an advisory services ... ranked Oracle as the number one vendor for enterprise life sciences software ... Software Top 10 identifies the 10 leading enterprise and specialty software vendors ...
    Cached Medicine News:Health News:Physician Dissatisfaction Leads to New Medical Conference 2Health News:Physician Dissatisfaction Leads to New Medical Conference 3Health News:Data Development Worldwide Helps Pharmaceutical Marketers Optimize Relationship Marketing to Patients 2Health News:A Pet's Bite Can Pass on MRSA 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 2Health News:Health-Care Reform Could Be Obama's Toughest Challenge 3Health News:Health-Care Reform Could Be Obama's Toughest Challenge 4Health News:Sechrist Industries Introduces Ground-Check System to Verify NFPA Ground Requirements in Hyperbaric Chambers 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 3
    Acuity Astigmatism: Letter Acuity, Astigmatic Clock, Number Acuity, and Tumbling E Tests....
    ... laboratory analysis that measures a substance produced by ... Annual PSA testing is a safe and effective ... as prostate cancer. One BIOSAFE Collection Kit, ... BIOSAFE's CLIA Certified Laboratory, and review of results ...
    Stereo Smile II also includes a blank card and tests,at 60, 120, 240 and 480 sec of arc., ,Smile Test II Includes:, 1 demonstration card, 1 pair pediatric 3-D viewers, 1 pair infant 3-D v...
    ... from 800 to 40 seconds ... as 2 years of age ... left to right., ,Randot Preschool ... #1: 200 & 100 sec ...
    Medicine Products: